Back to News
Market Impact: 0.35
Kiniksa Pharmaceuticals, Ltd. Reports Q3 2026 Net Product Revenue of $286.0 million
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Kiniksa Pharmaceuticals reported third-quarter 2026 total revenue of $286.0 million, up from $180.9 million in the third quarter of 2025, an increase of approximately 58%. ARCALYST net product revenue was $286.0 million; the provided article text is truncated before further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
KNSA0.60
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Tech's relief rally extends as attention turns to tough decisions for the Fed
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios